Vancouver, British Columbia and Princeton, New Jersey--(Newsfile Corp. - February 22, 2024) - Xybion Digital Inc. (TSXV: XYBN), a global, low-code SaaS company that enables digital transformation in life sciences and health organizations, the acceleration of new drug development and enables organizations to maintain employee health and safety, today reported financial results for its third quarter ending on December 31, 2023. Financial references are expressed in US dollars unless otherwise indicated. Please refer to the MD&A and Financial Statements posted onto SEDAR () for information relating to non-IFRS measures and risk factors.

Financial Highlights for Q3 2024 - December 31, 2023:

• Adjusted EBITDA (non-IFRS measure) of $631,086 in Q2 2024, compared to $(1,452,748) in Q2 2023, an increase of 143.4%. Adjusted EBITDA margin of 15.8%, as compared to (37.1)% in Q2 2023.
• Recurring revenue from Subscriptions and Maintenance for Q2 of 2024
• increased by 3.9% to $2.66 M, as compared to $2.56M in Q2 of 2022
• Annual Recurring Revenue (ARR) at Q2 2024 increased by 3.2% or $.33 million to $10.67 million, as compared to $10.34 million at Q2 2023.
• Overall quarterly revenue increased by 2.3% to $4.00 million, as compared to $3.91 million in Q2 2023.
• Net income of $334,893 in Q2 2024, compared to a net loss of $(1,224,637) in Q2 2023, an increase of 127.3%.
• As of September 30, 2023 the company had $6,831,804 million in cash on the balance sheet and zero debt.

"As I recently reported, I am pleased that we returned to our profitable growth trajectory in our Q3 and Q4 for the fiscal 2023 and that this has continued through Q3 of fiscal year 2024," stated Pradip Banerjee, CEO of Xybion "During this time we have been executing our strategy of managing our existing business and carrying out selective acquisitions to offer more comprehensive solutions to our clients," continued Dr. Banerjee.

"I am pleased to report that on November 16th we completed the acquisition of Autoscribe, a globally recognized LIMS software provider, headquartered in the United Kingdom, with additional operations in the United States and Australia. Autoscribe LIMS provides multi-industry domain solutions, easy to use and configure software that is currently used by over 140 customers. This acquisition aligns with Xybion's vision of fast-tracking lab digitization and information management SaaS solutions to simplify lab operations and speed up innovation," concluded Dr. Banerjee.

Non- IFRS Financial Measures

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS financial measures. EBITDA is defined as net income or loss before net finance expenses, depreciation and amortization expense and income tax expense. Adjusted EBITDA is defined as net income or loss before income taxes, net finance costs, depreciation and amortization, Paycheck Protection Payment (PPP) loan forgiveness, one-time Reverse Takeover (RTO) expenses and stock-based compensation, and Adjusted EBITDA Margin is defined as the percentage of Adjusted EBITDA to revenues. Since the Company capitalizes its operating leases as right of use assets, the amount of amortization related to these right of use (ROU) assets was not added back to earnings in determining Adjusted EBITDA. We believe that Adjusted EBITDA and Adjusted EBITDA Margin are useful measures of financial performance because they provide an indication of the Company's ability to seize growth opportunities in a cost-effective manner and finance its ongoing operations. Each of these non-IFRS financial measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS. These measures are unlikely to be comparable to similar measures presented by other companies. Rather, non-IFRS measures are provided as additional information to complement financial statements by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.

About Xybion Digital Inc.

Xybion is a global SaaS company that helps enterprise life sciences organizations accelerate new drug development into approved medicines that may save lives and keep employees safe. We digitize drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single, unified cloud platform that is cost-effective, ready to deploy, and easy to use. Xybion has over 160 clients in 29 countries using its software to accelerate timelines, improve compliance, expand capacity, minimize operating risks, and reduce expenses while keeping employees safe.

Learn more about Xybion at .

For further information: For more information regarding Xybion Digital Inc., please contact Pradip Banerjee, Chief Executive Officer, PBanerjee@xybion.com, 609-512-5790 x122

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements ("forward-looking statements") in this news release may contain forward-looking information concerning relating to the release of financial results, plans related to the Company's business and other matters that may occur in the future, made as of the date of this news release. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including with respect to the timing of such release. Although management considers these assumptions to be reasonable based on information available to it, they may prove to be incorrect.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the expectations expressed in them. Such factors include, among others, the risks described in disclosure documents filed by the Company on SEDAR. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES